RE: BSspiral: ONC has 19 months of cash on handDD
so you also seem to want to give the "informed" impression that the costs of developing a manufacturing process to produce reovirus will be more than the costs of conducting trials to actually get it approved (so they have a chance to use that manufacturing process)
great logic - but i prefer not to ignore reality ie., the costs of restart of the phase I glio trials, the US based phase II glio & systemic trials and the ph II pivotal trial, presumably also in $US
plus i didn't include the operating expenses of $500K/qtr (you know salaries & office supplies & stuff) in my previous review, so they probably are getting very close to 6 months of cash left, not the 9 i suggested earlier.
but you can go right on dreaming about those 19 months. i won't attempt to further disturb your delusions.
